WO2023139187 - GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/139187
Publication Date
27.07.2023
International Application No.
PCT/EP2023/051315
International Filing Date
20.01.2023
Title **
[English]
GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF
[French]
PROMÉDICAMENTS CO-AGONISTES DU RÉCEPTEUR GLP-1/GIP ET LEUR UTILISATION
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
KNERR, Patrick James
5225 Exploration Drive
Indianapolis, Indiana 46241, US
FINAN, Brian Patrick
5225 Exploration Drive
Indianapolis, Indiana 46241, US
Priority Data
63/301,311
20.01.2022
US
22154309.3
31.01.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1620 | |
| EPO | Filing, Examination | 5960 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 2710 |
Total: 11492 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological 5 conditions through a non-enzymatic reaction driven by chemical instability.[French]
L'invention concerne des composés de promédicaments de co-agonistes du récepteur du GLP-1/GIP, les co-agonistes du récepteur du GLP-1/GIP ayant été modifiés par la liaison d'un dipeptide au co-agoniste du récepteur du GLP-1/GIP par l'intermédiaire d'une liaison amide. Les promédicaments selon l'invention ont des demi-vies prolongées et sont convertis en co-agoniste actif du récepteur GLP-1/GIP dans des conditions physiologiques par une réaction non enzymatique induite par une instabilité chimique.